一个机器学习管道用于使用多模式数据对阿尔茨海默病的预后建模.
Luisa De Palma1, Vito Ivano D'Alessandro1, Filippo Attivissimo1
1Department of Electrical and Information Engineering, Polytechnic University of Bari, Via E. Orabona 4, 70125 Bari, Italy.
Sensors (Basel, Switzerland)
|March 14, 2026
概括
预测阿尔茨海默病 (AD) 的进展至关重要. 我们的研究开发了一个数据驱动的管道,使用多式联运数据,实现高精度与最小的特征早期干预.
科学领域:
- 神经科学是一个神经科学.
- 生物统计学 生物统计学
- 医疗信息学 医疗信息学
背景情况:
- 准确预测阿尔茨海默病 (AD) 的进展对于及时干预至关重要.
- 现有的预后模型经常与异构的多式联运数据和缺失的值作斗争.
研究的目的:
- 开发一个强大的,数据驱动的生存分析管道,用于预测从认知正常 (CN) 和轻度认知障碍 (MCI) 到AD的进展时间.
- 整合各种生物标志物,包括认知,临床,神经成像 (MRI/PET) 和生物样本数据.
主要方法:
- 利用了阿尔茨海默病神经成像计划 (ADNI) 数据集,这是一个多中心平台,用于多式联络数据集成.
- 开发了一条协调的预处理管道,以确保对跨站点和跨仪器变化的稳定性.
- 采用极端梯度提升 (XGBoost) 进行生存分析,能够本地处理丢失的数据.
主要成果:
- 实现了0.92的高协同指数 (C指数),其中13个特征和0.90只有4个特征.
- 通过多域功能集成和透明的功能选择,表现出强大的预测性能.
- 突出了未被充分研究的生物标志物的预后价值,例如脂质代谢物.
结论:
- 多域特征集成对于在阿尔茨海默病中准确的预后建模至关重要.
- 最少的一组精心挑选的特征可以产生高预测准确度.
- 结合新的生物标志物,如脂质代谢物,可以提高阿尔茨海默氏症进展模型的预测能力.
相关概念视频
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K


